AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33618395
Drug: Early stage
RxNorm normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early stage periarticular injection
Trial: 33618395
Drug: Late stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late stage periarticular injection
Trial: 33200439
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education (OHE), toothbrushes, fluoride toothpaste, and fluoride varnish on up to six occasions
Trial: 36360757
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (4-month daily micronutrient packets)
Trial: 33755846
Drug: Vasopressor administration
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressor administration (phenylephrine and noradrenaline)
Trial: 32940745
Drug: Interdisciplinary multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary multimodal assessment by pain medicine specialists, physiotherapists, and clinical psychologists.
Trial: 33746023
Drug: Ranibizumab (intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (intravitreal anti-VEGF agents)
Trial: 32780999
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human antithrombin 250 mg loading dose followed by continuous infusion of 2000 mg per 24 hours
Trial: 32780999
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical saline infusion)
Trial: 35801003
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitors (PPIs) and H2 blockers
Trial: 34836236
Drug: Peanut Protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Protein Supplementation (PP; 75 total g/d of powder providing 30 g/d protein, >9.2 g/d essential amino acids, 315 kcal/d)
Trial: 34836236
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-supplement group; CTL; n = 16 females, n = 8 males)
Trial: 33368960
Drug: LY2140112 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2140112 (LY) 100 mg
Trial: 33368960
Drug: LY2140112 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2140112 (LY) 130 mg
Trial: 33368960
Drug: LY2140112 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2140112 (LY) 5-75 mg
Trial: 36498818
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified, but implied as standard treatment or placebo.
Trial: 32326806
Drug: GLP-1RA +
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GLP-1RA + SGLT-2i (combination therapy)
Trial: 32326806
Drug: Control (Insulin)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (Insulin)
Trial: 35490936
Drug: Vasopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (20 IU) and Methylprednisolone (40 mg)
Trial: 34531021
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no-tablet months)
Trial: 35191924
Drug: Sublingual dexmedetomidine
RxNorm normalized name: dexmedetomidine Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual dexmedetomidine 180 μg
Trial: 35191924
Drug: Sublingual dexmedetomidine
RxNorm normalized name: dexmedetomidine Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual dexmedetomidine 120 μg
Trial: 34025637
Drug: Chemotherapy-allo-HSCT
RxNorm normalized name: allo-2-hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-allo-HSCT
Trial: 32890299
Drug: Intraoperative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative wound infiltration with local anesthetics, morphine sulfate, epinephrine, and nonsteroidal anti-inflammatory drugs; postoperative patient-controlled analgesia (PCA).
Trial: 32890299
Drug: Intraoperative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative wound infiltration with multimodal drugs; postoperative patient-controlled analgesia (PCA).
Trial: 34678128
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at 45 μg/kg ideal body weight/h (iNO45)
Trial: 32033612
Drug: Protective lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective lung ventilation (VT set at 6 ml/kg of predicted body weight with individualized PEEP during dura opening)
Trial: 32033612
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (VT set at 8 ml/kg of predicted body weight, no PEEP or recruitment maneuvers)
Trial: 35324339
Drug: Tapering group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering group (0.4mg/kg/day of methylprednisolone orally for 7 days, followed by progressive reduction of 8 mg per week for 3 weeks)
Trial: 35289004
Drug: Occupational therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy-based intervention
Trial: 35023557
Drug: Sodium Benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Benzoate (250-1500 mg/d)
Trial: 35023557
Drug: Sertraline (25-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-150 mg/d)
Trial: 32537732
Drug: Matrix rhythm
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix rhythm therapy (MRT) combined with Bobath therapy (BT)
Trial: 32537732
Drug: Bobath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath therapy (BT)
Trial: 35509085
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral ferrous sulfate (60 mg of elemental iron) daily for 12 weeks
Trial: 35509085
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral ferrous sulfate (60 mg of elemental iron) every other day for 12 weeks
Trial: 35332040
Drug: HN001 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HN001 capsules
Trial: 32526362
Drug: Curative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative treatment
Trial: 32526362
Drug: Active UIA
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active UIA treatment
Trial: 32526362
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment or surgical treatment
Trial: 32384727
Drug: Three-day bamboo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day bamboo forest therapy session
Trial: 33647776
Drug: Multi-component combination
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component combination of HQD (MCHD)
Trial: 33118309
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin users with continuous glucose monitoring (CGM)
Trial: 34925044
Drug: Ginkgolide® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgolide® treatment with IV rt‐PA
Trial: 34925044
Drug: Ginkgolide® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgolide® treatment with IV rt‐PA after propensity score matching
Trial: 32948867
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (WP) combined with low-fiber (LoFi; 10 g dietary fiber/day)
Trial: 32418856
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) administered intraoperatively after open arthrolysis
Trial: 32418856
Drug: Saline administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administration (control group)
Trial: 32145206
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity pulsed ultrasound (LIPUS) stimulation (1.5 MHz, 30 mW/cm2) for 20 minutes daily on postoperative days 4, 8, 14, and 20
Trial: 34387520
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 60,000 IU weekly for 8 weeks
Trial: 33941219
Drug: Hylan G‐F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G‐F 20
Trial: 32076718
Drug: Prophylaxis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis therapy
Trial: 35715946
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors (including sitagliptin)
Trial: 34424530
Drug: Decitabine monotherapy
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine monotherapy (control arm)
Trial: 34424530
Drug: Decitabine in
RxNorm normalized name: decitabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine in alternating cycles with sapacitabine (study arm) in patients with white blood cell counts <10 × 10^9 /L
Trial: 34424530
Drug: Decitabine monotherapy
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine monotherapy (control arm) in patients with white blood cell counts <10 × 10^9 /L
Trial: 32786002
Drug: Benzodiazepine receptor
RxNorm normalized name: GABA-benzodiazepine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine receptor agonists (BZRAs)
Trial: 34181474
Drug: Critically drug-resistant
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically drug-resistant E. coli
Trial: 34181474
Drug: Critically drug-resistant
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically drug-resistant K. pneumoniae
Trial: 34181474
Drug: Critically drug-resistant
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically drug-resistant Acinetobacter baumannii
Trial: 34181474
Drug: Critically drug-resistant
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically drug-resistant Pseudomonas aeruginosa
Trial: 32442781
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (10 sessions)
Trial: 36239914
Drug: Senaparib 100
RxNorm normalized name: Senaparib
DrugBank: Senaparib (DB17163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib 100 mg in fasted state
Trial: 36239914
Drug: Senaparib 100
RxNorm normalized name: Senaparib
DrugBank: Senaparib (DB17163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib 100 mg in fed state
Trial: 33862206
Drug: Laparoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic treatment (group 1), 13 patients, 2 required conversion to open surgery.
Trial: 32979074
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Exercise Training
Trial: 36266683
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (4,000 units daily for 18 weeks)
Trial: 34215149
Drug: IMPULS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPULS treatment (8 weekly sessions)
Trial: 34297338
Drug: Amikacin 25
RxNorm normalized name: amikacin 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 25 mg/kg intravenously
Trial: 34297338
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg intravenously
Trial: 34297338
Drug: Amikacin 25
RxNorm normalized name: amikacin 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 25 mg/kg and 15 mg/kg
Trial: 34810217
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus endocrine therapy (ET group, n = 196)
Trial: 34810217
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (CT group, n = 196)
Trial: 33085058
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oxaliplatin 130 mg/m2 (SOX130)
Trial: 34261793
Drug: Original VRC26.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original VRC26.25 antibody
Trial: 32058608
Drug: Needleless administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Needleless administration of SCIT
Trial: 32058608
Drug: Traditional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional administration of SCIT
Trial: 35021944
Drug: Nanocurcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (80 mg/day for 8 weeks)
Trial: 36104138
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg on day 1 of the first week of each 8-week cycle, alternating with NIVO 480 mg monotherapy on day 1 of the fifth week of each 8-week cycle
Trial: 36104138
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg
Trial: 36154660
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral treatment for hepatitis C virus (HCV)
Trial: 33158777
Drug: Intraluminal brachytherapy
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal brachytherapy using 125I seed strand and CT‐guided percutaneous radioactive seed implantation therapy
Trial: 33158777
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with gemcitabine and cisplatin
Trial: 32591274
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no L-PRF)
Trial: 32507285
Drug: I-gel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel®
Trial: 35841075
Drug: Ethanol‐based handrub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol‐based handrub gel with superfatting agents (Saniswiss Sanitizer Hands H1)
Trial: 35841075
Drug: Isopropanol‐based formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropanol‐based formulations (Hopirub® or Hopigel®)
Trial: 33780276
Drug: Neoadjuvant chemohormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemohormonal therapy and radical prostatectomy
Trial: 36660974
Drug: High-intensity multimodal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity multimodal exercise training (HIT-MMEX) - supervised resistance, weight-bearing, balance and mobility training twice weekly for 8 months
Trial: 34637848
Drug: Intensive community-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive community-based intervention (weekly group activities including physical activity and education)
Trial: 36401471
Drug: Xiehuangjiejing (XHJJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiehuangjiejing (XHJJ) granule, 4.5 g administered 3 times daily
Trial: 36401471
Drug: Matched placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo, 4.5 g administered 3 times daily
Trial: 33960277
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg daily for three months)
Trial: 33119423
Drug: lemborexant 5
RxNorm normalized name: lemborexant 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant 5 mg/day
Trial: 33119423
Drug: lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant 10 mg/day
Trial: 33119423
Drug: lemborexant (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant (5 mg/day or 10 mg/day)
Trial: 33306634
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg effervescent tablets, three tablets per day for two days prior to RNT)
Trial: 33706868
Drug: Platelet reactivity-based
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet reactivity-based strategy (daily measurements of platelet reactivity by Multiplate analyzer)
Trial: 33706868
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (P2Y12 receptor inhibitor withdrawn 5 to 7 days before CABG)
Trial: 34545997
Drug: Cilostazol (CLS)
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol (CLS) 50 mg twice daily plus escitalopram (ESC) 20 mg once daily for six weeks
Trial: 34545997
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus escitalopram (ESC) 20 mg once daily for six weeks
Trial: 34973597
Drug: Salsalate (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (1500 mg, twice daily for 4 days)
Trial: 32133585
Drug: L-tyrosine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine (2.0 g)
Trial: 34967382
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency therapy
Trial: 34589205
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherries (MC) 30 ml twice daily for 28 days
Trial: 34589205
Drug: Placebo 30
RxNorm normalized name: Ethinyl Estradiol/Norgestrel;Placebo 30 MCG-0.3 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 ml twice daily for 28 days
Trial: 32223116
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation plus clopidogrel
Trial: 32068870
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (0.75-6 mg, dosing interval 0.75 mg)
Trial: 35459947
Drug: Physiological IntraCytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological IntraCytoplasmic Sperm Injection (PICSI)
Trial: 32281648
Drug: Higher threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher threshold (e.g., P < .2)
Trial: 35731517
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin 100 mg daily
Trial: 32590944
Drug: Intracoronary prourokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary prourokinase (10 ml)
Trial: 34602290
Drug: Rucaparib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib treatment
Trial: 35977778
Drug: Intrathecal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal hydromorphone (100 μg)
Trial: 33013880
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g TXA
Trial: 33013880
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g TXA
Trial: 35834738
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care overground therapy
Trial: 33817809
Drug: Adjunctive phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive phototherapy protocol ('Perio‐1') with root surface debridement (RSD)
Trial: 33817809
Drug: Adjunctive phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive phototherapy protocol ('Perio‐1') with RSD
Trial: 33228744
Drug: Active psychological
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active psychological treatments for depression (specific treatments not detailed)
Trial: 32481364
Drug: Huangqi Guizhi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huangqi Guizhi Wuwu decoction mimetic agent
Trial: 33236662
Drug: Moderate fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate fixed-dose hydroxyurea (20 mg/kg/day)
Trial: 33236662
Drug: Low fixed-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low fixed-dose hydroxyurea (10 mg/kg/day)
Trial: 34320708
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 50 mg dexketoprofen